Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.

Article  PubMed  CAS  Google Scholar 

Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.

Article  PubMed  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-Baimani K, Jonker H, Zhang T, et al. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? Curr Oncol. 2018;25(4):e291–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Templeton AJ, Booth CM, Tannock IF. Informing patients about expected outcomes: the efficacy-effectiveness gap. J Clin Oncol. 2020;38(15):1651–4.

Article  PubMed  Google Scholar 

Pasello G, Pavan A, Attili I, et al. Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer. Cancer Treat Rev. 2020;87: 102031.

Article  PubMed  CAS  Google Scholar 

Green AK, Curry M, Trivedi N, Bach PB, Mailankody S. Assessment of outcomes associated with the use of newly approved oncology drugs in medicare beneficiaries. JAMA Netw Open. 2021;4(2):e210030.

Article  PubMed  PubMed Central  Google Scholar 

Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.

Article  PubMed  Google Scholar 

Takada K, Shimokawa M, Mizuki F, et al. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials. Eur J Med Res. 2022;27(1):157.

Article  PubMed  PubMed Central  Google Scholar 

Tibaldi C, Mazzoni F, Scotti V, et al. Pembrolizumab for first-line treatment of advanced non-small-cell lung cancer: analysis of prognostic factors of outcomes. Anticancer Agents Med Chem. 2022;22(7):1278–85.

Article  PubMed  CAS  Google Scholar 

Zhao C, Wang F, Huang J, et al. The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer. Eur J Clin Pharmacol. 2021;77(5):685–95.

Article  PubMed  CAS  Google Scholar 

Chen Z, Yin K, Zheng D, et al. Marital status independently predicts non-small cell lung cancer survival: a propensity-adjusted SEER database analysis. J Cancer Res Clin Oncol. 2020;146(1):67–74.

Article  PubMed  Google Scholar 

Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol. 2023;9(3):334–41.

Article  PubMed  PubMed Central  Google Scholar 

Cramer-van der Welle CM, Verschueren MV, Tonn M, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep. 2021;11(1):6306.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156:41–9.

Article  PubMed  CAS  Google Scholar 

Khozin S, Carson KR, Zhi J, et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist. 2019;24(5):648–56.

Article  PubMed  CAS  Google Scholar 

Leapman MS, Presley CJ, Zhu W, et al. Association of programmed cell death ligand 1 expression status with receipt of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. JAMA Netw Open. 2020;3(6):e207205.

Article  PubMed  PubMed Central  Google Scholar 

Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–80.

Article  PubMed  Google Scholar 

Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340–66.

Article  PubMed  CAS  Google Scholar 

Carroll R, Bortolini M, Calleja A, et al. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC Cancer. 2022;22(1):255.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.

Article  PubMed  CAS  Google Scholar 

Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. Thorac Oncol. 2019;14(5):867–75.

Article  CAS  Google Scholar 

Li F, Zhai S, Lv Z, et al. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:968517.

Article  PubMed  PubMed Central  CAS  Google Scholar